Anika Therapeutics (ANIK) Cash from Investing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Investing Activities data on file, last reported at -$1.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$1.2 million, down 174.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (up 31.77% YoY), and the FY2025 annual result was -$401000.0, up 95.19% from the prior year.
• Cash from Investing Activities fell to -$1.2 million in Q1 2026 per ANIK's latest filing, from $198000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.7 million in Q1 2025 and troughed at -$3.4 million in Q2 2024.
• A 5-year average of -$1.3 million and a median of -$1.5 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 176.47% in 2022, then soared 192.48% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$2.5 million in 2022, then increased by 27.24% to -$1.8 million in 2023, then gained by 28.97% to -$1.3 million in 2024, then jumped by 115.15% to $198000.0 in 2025, then tumbled by 725.76% to -$1.2 million in 2026.
• Business Quant data shows ANIK's Cash from Investing Activities at -$1.2 million in Q1 2026, $198000.0 in Q4 2025, and -$1.7 million in Q3 2025.